Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal bevacizumab for subfoveal choroidal neovascularization due to age-related macular degeneration
2006-002424-42Phase 2Completed
- Sponsor
- IRCCS Ospedale Sacro Cuore Don Calabria
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in age-related macular degeneration (AMD), sponsored by IRCCS Ospedale Sacro Cuore Don Calabria. Primary endpoint: Safety of intravitreal bevacizumab. Started Jun 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2006-002424-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002424-42.